LifeMD, Inc. USDC – Eastern District of New York august 27, 2025 CLASS PERIOD: May 7, 2025 – August 5, 2025LEAD PLAINTIFF DEADLINE: OCTOBER 27, 2025 Please complete the form below to contact Kaplan Fox regarding the LifeMD Investigation: Join a Case First Name * Last Name * Email Address * Phone Number * Ticker Symbol Or Company Name * Please Insert Your Estimation Of Losses In USD * Are you a current or former employee of the company mentioned having traded above? * Yes No Captcha Submit If you are human, leave this field blank. Principle Contacts Pamela MayerPMayer@kaplanfox.comLaurence D. KingLKing@kaplanfox.com Kaplan Fox Alerts Investors of LifeMD, Inc. (LFMD) to a Securities Class Action Deadline on October 27, 2025 Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against LifeMD, Inc. (“LifeMD” or the “Company”) (NASDAQ: LFMD) on behalf of investors that purchased or otherwise acquired LifeMD securities between May 7, 2025 and August 5, 2025 (the “Class Period”). CLICK HERE TO JOIN THE CASE If you purchased LifeMD securities during the Class Period and have suffered losses, you may CLICK HERE to contact us. You may also contact Kaplan Fox by emailing pmayer@kaplanfox.com or by calling (646) 315-9003. DEADLINE REMINDER: If you are a member of the proposed Class, you may move the court no later than October 27, 2025 to serve as a lead plaintiff for the purported class. If you have losses, we encourage you to contact us to learn more about the lead plaintiff process. You need not seek to become a lead plaintiff in order to share in any possible recovery. On May 6, 2025, after markets closed and in connection with reporting first quarter 2025 financial results, the Company issued a press release that states “[w]e are raising our full-year 2025 guidance to reflect our strong performance” and “we now expect total revenues in the range of $268 to $275 million, up from $265 to $275 million. . ..” The press release also states “[o]ur recently announced strategic collaborations with both LillyDirect and NovoCare continue to generate momentum by allowing us to offer more convenient and affordable access to branded GLP-1 medications.” Then, on August 5, 2025, after markets closed, the Company issued a press release announcing second quarter 2025 financial results, including revising full-year 2025 guidance downward to a range of $250 million to $255 million, compared with previous guidance of $268 million to $275 million “[d]ue to some temporary challenges facing our RexMD business-which are now largely resolved. . .” According to the complaint, during the conference call that followed, LifeMD’s Chief Executive Officer disclosed that the Company’s weight management business “has been impacted by a higher-than-anticipated refund rate driven by patients either lacking insurance coverage for their medications or being unable to afford the out-of-pocket cost of branded therapies” and that “[LifeMD] experienced a challenging second quarter, primarily due to temporarily elevated customer acquisition costs in the highly competitive ED market.” Following this news, the price of LifeMD’s shares fell $5.31 per share, nearly 45%, to close at $6.53 per share on August 6, 2025. The complaint alleges, among other things, that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that defendants were reckless in raising LifeMD’s 2025 guidance, considering that they had not properly accounted for rising customer acquisition costs in LifeMD’s RexMD segment. WHY CONTACT KAPLAN FOX Kaplan Fox is a leading national law firm focusing on complex litigation with offices in New York, Oakland, Los Angeles, Chicago and New Jersey. With over 50 years of experience in securities litigation, Kaplan Fox offers the professional experience and track record that clients demand. Through prosecuting cases on the federal and state levels, Kaplan Fox has successfully shaped the law through winning many important decisions on behalf of our clients. For more information about Kaplan Fox & Kilsheimer LLP, you may visit our website at www.kaplanfox.com. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. If you have any questions about this Notice, your rights, or your interests, please contact: CONTACT:Pamela A. MayerKAPLAN FOX & KILSHEIMER LLP800 Third Avenue, 38th FloorNew York, New York 10022(646) 315-9003pmayer@kaplanfox.com Laurence D. KingKAPLAN FOX & KILSHEIMER LLP1999 Harrison Street, Suite 1560Oakland, California 94612(415) 772-4704lking@kaplanfox.com The submission of this form does not create an attorney-client relationship, nor an obligation on the part of Kaplan Fox to retain you as a client. Any information you submit will be maintained as confidential. If Kaplan Fox, in its sole discretion, believes that you might be an appropriate client, Kaplan Fox will contact you to discuss the matter and whether to establish an attorney client relationship. By signing this form you are authorizing us to contact you regarding this case and/or future cases. Connect with Kaplan Fox. Receive a complimentary case review now. Contact Us Dow, Inc. See the Case Semler Scientific, Inc. See the Case LifeMD, Inc. See the Case C3.ai, Inc. See the Case Snap, Inc. See the Case KinderCare Learning Companies, Inc. See the Case SelectQuote, Inc. See the Case Unicycive Therapeutics, Inc. See the Case Fiserv, Inc. See the Case Simulations Plus, Inc. See the Case Inspire Medical Systems, Inc. See the Case Western Asset Management See the Case
